Shunjl Tomatsu

Title: Shunjl Tomatsu: Innovator in Prenatal Enzyme Replacement Therapy

Introduction

Shunjl Tomatsu is a notable inventor based in Clayton, MO (US). He has made significant contributions to the field of prenatal medicine, particularly in the treatment of metabolic disorders.

Latest Patents

Tomatsu holds a patent for "Prenatal enzyme replacement therapy for hypophosphatasia." This innovative therapy involves transplacental enzyme replacement therapy (ERT) for deficiencies of a polypeptide, specifically tissue-nonspecific alkaline phosphatase (TNSALP). The method includes administering a pharmaceutical composition that comprises a water-soluble TNSALP portion, which is peptide-bonded to an IgG1 antibody Fc portion, to a pregnant animal whose fetus or embryo requires such therapy. This approach aims to treat metabolic disorders, such as hypophosphatasia (HPP), in fetuses or embryos by using a fusion protein that crosses the placenta and restores normal metabolic activity in the fetus.

Career Highlights

Shunjl Tomatsu is affiliated with Saint Louis University, where he continues to advance research in enzyme replacement therapies. His work has garnered attention for its potential to improve prenatal care and outcomes for affected fetuses.

Collaborations

Tomatsu collaborates with esteemed colleagues, including William S. Sly and Jeffrey H. Grubb, who contribute to the research and development of innovative therapies in the field.

Conclusion

Shunjl Tomatsu's work in prenatal enzyme replacement therapy represents a significant advancement in treating metabolic disorders in fetuses. His innovative approach has the potential to change the landscape of prenatal medicine and improve the lives of many.